High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome
- PMID: 17236108
- DOI: 10.1055/s-2006-955931
High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome
Abstract
Opsoclonus-myoclonus syndrome (OMS) is a rare movement disorder characterized by chaotic eye movements, myoclonus, and ataxia associated with severe irritability. Different treatment modalities including steroids and cyclophosphamide have been tried in the past often with significant side effects and variable success. Here we present 11 children, diagnosed with OMS between 1999 and 2005 and treated with high dose dexamethasone pulses. Main symptoms at presentation were opsoclonus (11/11), ataxia and/or myoclonus (11/11), irritability (10/11) associated with a neuroblastoma in four children. Number of dexamethasone pulses ranged from 6 to 60 pulses. No major side effects were reported. In 6/11 children a complete and sustained remission of OMS symptoms was achieved after 6 to 29 pulses of dexamethasone. Two children from this group have a normal development and no neurological sequelae. Two further children have minor delays in fine- and gross-motor skills. Two children despite a complete recovery of OMS symptoms have persisting developmental problems. 5/11 children still require regular dexamethasone pulses in addition to daily prednisolone (n = 1) or have received cyclophosphamide pulses meanwhile (n = 2). All children continue to have developmental and neurological difficulties. In summary treatment with high dose pulsatile dexamethasone appears to be safe and beneficial in a subgroup of patients with OMS.
Similar articles
-
Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses.Eur J Paediatr Neurol. 2008 Jan;12(1):51-5. doi: 10.1016/j.ejpn.2007.05.005. Epub 2007 Jul 10. Eur J Paediatr Neurol. 2008. PMID: 17625938
-
Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.Pediatr Blood Cancer. 2008 Mar;50(3):683-7. doi: 10.1002/pbc.21107. Pediatr Blood Cancer. 2008. PMID: 17226843 Clinical Trial.
-
Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.Pediatrics. 2002 Jan;109(1):86-98. Pediatrics. 2002. PMID: 11773546
-
[Opsoclonus-myoclonus syndrome].Medicina (B Aires). 2009;69(1 Pt 1):64-70. Medicina (B Aires). 2009. PMID: 19240003 Review. Spanish.
-
The Treatment of Opsoclonus-Myoclonus Syndrome Secondary to Neuroblastic Tumours-Single-Centre Experience and Literature Review.Medicina (Kaunas). 2020 Aug 14;56(8):412. doi: 10.3390/medicina56080412. Medicina (Kaunas). 2020. PMID: 32823831 Free PMC article. Review.
Cited by
-
Opsoclonus myoclonus.Innov Clin Neurosci. 2011 Dec;8(12):29-31. Innov Clin Neurosci. 2011. PMID: 22247816 Free PMC article.
-
Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part II-Use of Immunomodulatory Therapies.J Child Adolesc Psychopharmacol. 2017 Sep;27(7):574-593. doi: 10.1089/cap.2016.0148. Epub 2017 Jul 19. J Child Adolesc Psychopharmacol. 2017. PMID: 36358107 Free PMC article.
-
Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.Front Neurol. 2017 Sep 11;8:468. doi: 10.3389/fneur.2017.00468. eCollection 2017. Front Neurol. 2017. PMID: 28959231 Free PMC article.
-
Neurological Complications of Pediatric Cancer.J Child Neurol. 2016 Oct;31(12):1412-20. doi: 10.1177/0883073815620673. Epub 2015 Dec 29. J Child Neurol. 2016. PMID: 26719497 Free PMC article. Review.
-
Opsoclonus-myoclonus syndrome after adenovirus infection.Springerplus. 2015 Oct 23;4:636. doi: 10.1186/s40064-015-1429-1. eCollection 2015. Springerplus. 2015. PMID: 26543770 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous